Drugs / Ramosetron
Ramosetron
also known as
YM060 · Nasea · (r)-(-)-ramosetron hydrochloride · Irribow · Nasea - ramosetron · NaseaTM · Ramosetron Hydrochloride · ramosetron(nasea)
Trials 37 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02869984 | Aug 2016 → Oct 2018 | — | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT01394653 | Jul → Aug 2011 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT01392794 | Apr → May 2011 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT01788605 | Aug → Dec 2014 | hematopoietic and lymphoid cell neoplasm | The Catholic University of Korea | Unknown | No outcome recorded |
| Phase 2 | NCT01806948 | Apr 2013 → Oct 2014 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01274000 | Nov 2010 → Oct 2011 | irritable bowel syndrome | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT01012336 | May 2010 → Oct 2011 | chemotherapy-induced toxicity, ovarian carcinoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01046461 | Jan 2010 → Mar 2012 | cancer | Hallym University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00189813 | Mar → Dec 2005 | irritable bowel syndrome | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06166615 | Dec 2023 → May 2024 | — | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT02830906 | Apr 2014 → Feb 2015 | — | Thammasat University | Completed | No outcome recorded |
| Phase 3 | NCT01870895 | Feb 2013 → Feb 2014 | irritable bowel syndrome | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT01736423 | Sep 2012 → May 2014 | irritable bowel syndrome | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT01536691 | Jun 2011 → Nov 2012 | cancer | Hallym University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00971399 | Sep 2009 → Feb 2011 | chemotherapy-induced toxicity | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00272285 | Jan 2006 → Dec 2007 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT00189696 | — | irritable bowel syndrome | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT07574320 | Apr 2026 → Jan 2027 expected | irritable bowel syndrome | Md. Aminul Islam | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05326360 | Dec 2020 → Oct 2021 | female breast carcinoma | Pusan National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04297293 | May 2020 → Feb 2022 | — | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02849483 | Jul 2016 → Jul 2017 | — | Kyunghee University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02532634 | Aug 2015 → May 2018 | cancer | Kangdong Sacred Heart Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02803788 | Jul 2015 → Jul 2016 | — | Government Medical College, Haldwani | Unknown | No outcome recorded |
| Phase 4 | NCT02478645 | Jun 2015 → Feb 2016 | — | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT02480088 | Sep 2014 → Mar 2015 | — | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01427127 | Dec 2010 → Dec 2011 | — | Kyunghee University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01225237 | Oct 2010 → Aug 2011 | irritable bowel syndrome | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT01102491 | Sep 2009 → Feb 2010 | osteoarthritis, knee | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00918411 | Jun → Dec 2009 | irritable bowel syndrome | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT05577845 | Mar 2023 → Dec 2025 overdue | — | Seoul National University Hospital | Recruiting | No outcome recorded |
| — | NCT03409835 | Mar 2018 → Feb 2019 | — | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| — | NCT03232125 | Aug 2017 → Jun 2020 | prostate cancer | Yonsei University | Completed | No outcome recorded |
| — | NCT03017222 | Sep 2015 → Apr 2016 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT02416115 | Jul → Sep 2014 | — | Kyungpook National University Hospital | Completed | No outcome recorded |
| — | NCT02139241 | Jun 2013 → Oct 2014 | coronary artery disorder, hypotensive disorder | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT01825733 | Aug 2011 → Jul 2012 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT01169805 | Aug 2010 → Jun 2011 | non-congenital cyst of kidney | Yonsei University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 21 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01703351 Comparator | Oct 2012 → Nov 2015 | lung neoplasm | Yonsei University | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02011659 Comparator | Nov 2013 → Nov 2015 | adenomyosis, leiomyoma, ovarian neoplasm | National Health Insurance Service Ilsan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02444897 Comparator | Sep 2013 → Dec 2014 | gastric cancer | Keimyung University Dongsan Medical Center | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT03278522 Comparator | Jul 2017 → Feb 2018 | — | Konkuk University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01637545 Comparator | Dec 2011 → Feb 2015 | disorder of facial skeleton | Seoul National University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01013012 Background | Jan → Nov 2008 | — | Yonsei University | Completed | No outcome recorded |
| Phase not applicable15 trials | ||||||
| — | NCT03462836 Comparator | Apr → Dec 2019 | colorectal cancer | Yonsei University | Withdrawn | No outcome recorded |
| — | NCT04061057 Background | Mar 2018 → Feb 2019 | rotator cuff syndrome | Yonsei University | Completed | No outcome recorded |
| — | NCT03171610 Comparator | Jun 2017 → Jan 2018 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT02625181 Background | Jul 2016 → Nov 2017 | — | Vanderbilt University | Completed | No outcome recorded |
| — | NCT02604797 Background | Jan 2016 → Jan 2017 | — | Fudan University | Unknown | No outcome recorded |
| — | NCT02617121 Comparator | Nov 2015 → Aug 2016 | — | Hallym University Medical Center | Unknown | No outcome recorded |
| — | NCT02509143 Background | Jul 2015 → Nov 2016 | colorectal neoplasm | Pusan National University Yangsan Hospital | Completed | No outcome recorded |
| — | NCT02478047 Comparator | Jun 2015 → Jun 2016 | chemotherapy-induced toxicity | Tianjin University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT02195921 Comparator | Apr 2015 → Mar 2016 | chemotherapy-induced toxicity | Tianjin University of Traditional Chinese Medicine | Completed | No outcome recorded |
| — | NCT02195908 Comparator | Aug 2014 → Jul 2015 | — | Tianjin University of Traditional Chinese Medicine | Completed | No outcome recorded |
| — | NCT02597907 Comparator | Jul 2014 → May 2015 | — | Kyungpook National University Hospital | Completed | No outcome recorded |
| — | NCT02076529 Comparator | Oct 2012 → Dec 2013 | colon carcinoma | Chonnam National University Hospital | Completed | No outcome recorded |
| — | NCT01669213 Comparator | Aug → Dec 2012 | hypotensive disorder | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT01476280 Comparator | May → Aug 2011 | — | Incheon St.Mary's Hospital | Completed | No outcome recorded |
| — | NCT01041183 Comparator | Nov → Dec 2009 | — | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 60 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ramosetron | “Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and...” NCT04061057 ↗49“5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.” NCT02195908 ↗ “PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.” NCT03171610 ↗ “5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron , Tropisetron)and dexamethasone are supplied from the first day of chemtherapy,and lasting for 3-5days.” NCT02195921 ↗ “IV PCA (fentanyl 10mcg/kg + nefopam (Acupan®) 80mg + Ramosetron (Nasea®) ) apply 30min before end of surgery.” NCT03462836 ↗ |
| Known as | (r)-(-)-ramosetron hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1643895 ↗ |
| Known as | Irribow | “5 μg of ramosetron (Irribow®) daily” PMID 33982068 ↗ Jun 2021 |
| Known as | Nasea | “Ramosetron (Nasea®)” NCT03462836 ↗ |
| Known as | Nasea - ramosetron | “Nasea - ramosetron” NCT01536691 ↗ |
| Known as | NaseaTM | “PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.” NCT03171610 ↗ |
| Known as | Ramosetron Hydrochloride | “Drug: Ramosetron Hydrochloride” NCT05326360 ↗ |
| Known as | ramosetron(nasea) | “ramosetron(nasea)” NCT02532634 ↗ |
| Known as | YM060 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01394653 ↗ |
| Action | Inhibit | “5-HT3 receptor antagonist” NCT00189696 ↗ |
| Modality | Small molecule | — CHEMBL1643895 ↗ |
| Route | Oral | “oral dose of YM060” NCT00189696 ↗ |